The aim of this study was to investigate whether gamma-mangostin could reduce fasting blood glucose, cholesterol, SGOT, SGPT, and also ameliorate damaged hepatocytes in diabetic mice. In this study, we used male BALB/C mice. Mice were divided into two groups: Normal control (KN) and streptozotocin-induced diabetic. Streptozotocin (STZ) induction was performed using multiple low doses of 30 mg/kg body weight injected for five consecutive days. The diabetic mice were separated into three subgroups: Diabetic control (KD), diabetic mice treated with acarbose (KA), and diabetic mice treated with gamma-mangostin at either 0,5 mg/kg body weight (P1), 1 mg/kg body weight (P2), or 2 mg/kg body weight (P3). Before and after STZ injection, fasting blood glucose and cholesterol level would be observed. Fasting blood glucose and cholesterol level were also measured at the 1 st , 7 th , and 14 th day of gamma-mangostin treatment. Treatment was given for 14 days. On the 15 th day, SGOT and SGPT were measured using a Pentra C 200 Reader, while the liver was collected and processed onto the histological slides. Interestingly, we found that gamma-mangostin was able to reduce the fasting blood glucose, cholesterol, SGOT, SGPT, and ameliorate the damaged hepatocytes in significant diabetic mice. Therefore, we concluded that gamma-mangostin is a promising anti-diabetic agent due to its anti-hyperglycemic and antioxidant activities.


Dive into the research topics of 'Hepatoprotective Effect of Gamma-mangostin for Amelioration of Impaired Liver Structure and Function in Streptozotocin-induced Diabetic Mice'. Together they form a unique fingerprint.

Cite this